Literature DB >> 16940116

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.

Geraint R Davies1, Richard Brindle, Saye H Khoo, Leon J Aarons.   

Abstract

Nonlinear mixed-effects analysis of serial sputum colony-counting data supports the existence of two bacillary subpopulations in sputum, eliminated at different rates. It distinguishes between combination regimens, removes bias, and greatly improves precision, with significant implications for the analysis of surrogate endpoints of "sterilization" in the development of new antituberculosis regimens.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940116      PMCID： PMC1563554          DOI： 10.1128/AAC.00774-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.

Authors:  F A Sirgel; P R Donald; J Odhiambo; W Githui; K C Umapathy; C N Paramasivan; C M Tam; K M Kam; C W Lam; K M Sole; D A Mitchison
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  Whole blood bactericidal activity during treatment of pulmonary tuberculosis.

Authors:  Robert S Wallis; Solange A Vinhas; John L Johnson; Fabíola C Ribeiro; Moisés Palaci; Renata L Peres; Ricardo T Sá; Reynaldo Dietze; Allan Chiunda; Kathleen Eisenach; Jerrold J Ellner
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

Review 3.  Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs.

Authors:  Denis A Mitchison; Anthony R M Coates
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 4.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

Authors:  W Fox; G A Ellard; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1999-10       Impact factor: 2.373

Review 5.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

6.  Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

Authors:  C N Paramasivan; S Sulochana; G Kubendiran; P Venkatesan; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis.

Authors:  M L Joloba; J L Johnson; A Namale; A Morrissey; A E Assegghai; R D Mugerwa; J J Ellner; K D Eisenach
Journal:  Int J Tuberc Lung Dis       Date:  2000-06       Impact factor: 2.373

8.  Evaluation of sputum decontamination methods for Mycobacterium tuberculosis using viable colony counts and flow cytometry.

Authors:  Tamara V N Burdz; Joyce Wolfe; Amin Kabani
Journal:  Diagn Microbiol Infect Dis       Date:  2003-11       Impact factor: 2.803

9.  Localisation of mycobacterial DNA and mRNA in human tuberculous granulomas.

Authors:  Gael Fenhalls; Liesel Stevens-Muller; Rob Warren; Nora Carroll; Juanita Bezuidenhout; Paul Van Helden; Philip Bardin
Journal:  J Microbiol Methods       Date:  2002-10       Impact factor: 2.363

10.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis.

Authors:  R Brindle; J Odhiambo; D Mitchison
Journal:  BMC Pulm Med       Date:  2001       Impact factor: 3.317
View more
  25 in total

1.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.

Authors:  Bas C Mourik; Gerjo J de Knegt; Annelies Verbon; Johan W Mouton; Hannelore I Bax; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 4.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

5.  Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.

Authors:  Isobella Honeyborne; Timothy D McHugh; Patrick P J Phillips; Selina Bannoo; Anna Bateson; Nora Carroll; Felicity M Perrin; Katharina Ronacher; Laura Wright; Paul D van Helden; Gerhard Walzl; Stephen H Gillespie
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

6.  Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Authors:  Nicholas D Walter; Gregory M Dolganov; Benjamin J Garcia; William Worodria; Alfred Andama; Emmanuel Musisi; Irene Ayakaka; Tran T Van; Martin I Voskuil; Bouke C de Jong; Rebecca M Davidson; Tasha E Fingerlin; Katerina Kechris; Claire Palmer; Payam Nahid; Charles L Daley; Mark Geraci; Laurence Huang; Adithya Cattamanchi; Michael Strong; Gary K Schoolnik; John Lucian Davis
Journal:  J Infect Dis       Date:  2015-03-11       Impact factor: 5.226

7.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

Review 8.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

9.  Treatment Effect Measures for Culture Conversion Endpoints in Phase IIb Tuberculosis Treatment Trials.

Authors:  Isabelle R Weir; Sean Wasserman
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

10.  Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.

Authors:  Derek J Sloan; Elizabeth L Corbett; Anthony E Butterworth; Henry C Mwandumba; Saye H Khoo; Aaron Mdolo; Doris Shani; Mercy Kamdolozi; Jenny Allen; Denis A Mitchison; David J Coleman; Geraint R Davies
Journal:  J Clin Microbiol       Date:  2012-05-09       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.